[L-Arg1]-Icatibant, also known by its CAS number 193618-59-6, is a synthetic peptide that functions as a selective bradykinin B2 receptor antagonist. It is primarily utilized in the treatment of conditions associated with excessive bradykinin activity, such as hereditary angioedema. The structure of [L-Arg1]-Icatibant includes an arginine residue at the first position, which is crucial for its binding affinity and specificity to the bradykinin receptor. This compound exhibits a high degree of potency and selectivity, making it effective in inhibiting bradykinin-induced vascular permeability and inflammation. In terms of physical properties, it is typically presented as a white to off-white powder, soluble in water, and stable under appropriate storage conditions. The pharmacological profile of [L-Arg1]-Icatibant highlights its role in modulating pain and swelling, providing therapeutic benefits in acute and chronic inflammatory conditions. As with any pharmacological agent, its use should be guided by clinical protocols and considerations of potential side effects.

[L-Arg1]-Icatibant

193618-59-6: [L-Arg1]-Icatibant, also known by its CAS number 193618-59-6, is a synthetic peptide that functions as a selective bradykinin B2 receptor antagonist. It is primarily utilized in the treatment of conditions associated with excessive bradykinin activity, such as hereditary angioedema. The structure of [L-Arg1]-Icatibant includes an arginine residue at the first position, which is crucial for its binding affinity and specificity to the bradykinin receptor. This compound exhibits a high degree of potency and selectivity, making it effective in inhibiting bradykinin-induced vascular permeability and inflammation. In terms of physical properties, it is typically presented as a white to off-white powder, soluble in water, and stable under appropriate storage conditions. The pharmacological profile of [L-Arg1]-Icatibant highlights its role in modulating pain and swelling, providing therapeutic benefits in acute and chronic inflammatory conditions. As with any pharmacological agent, its use should be guided by clinical protocols and considerations of potential side effects.

CAS 193618-59-6

[L-Arg1]-Icatibant

L-Arg(1)-Icatibant

Ref: ST-EA-CP-I55004